Appointment of Dr Tara Speranza as CEO & CTO
Filed with ASX · · 2 pages · English
Summary by 6ix AI
Dr Speranza has extensive experience in scientific research and commercial strategy within the healthcare and biotechnology sectors. The Chairman of Vectus expressed confidence that Dr Speranza's expertise aligns with the company's strategy to advance its lead program. Dr Speranza aims to progress the company's lead program into further clinical studies and engage with strategic partners.
Written by 6ix AI from the company’s filing. How 6ix writes summaries
Vectus Biosystems Limited on 6ix
Earlier from Vectus Biosystems
- VB4-P5 Renal Compound Transaction Settled
- Half Year Report & Appendix 4D
- Quarterly Activities & Appendix 4C Cash Flow Reports
- Response to ASX Query Letter
- Reinstatement to Quotation
Later from Vectus Biosystems
- Placement of Shares
- Application for quotation of securities - VBS
- Cleansing Notice
- Preliminary Final Report
- Full Year Statutory Accounts
Follow Vectus Biosystems into a list and get an email when it puts out news.
Follow Vectus Biosystems